Search results
Results from the WOW.Com Content Network
In leukemia, a type of blood cancer, the ability of your bone marrow to produce normal blood cells is compromised. Rapidly developing, abnormal white blood cells crowd out healthy white blood ...
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
Terminal lucidity (also known as rallying, terminal rally, the rally, end-of-life-experience, energy surge, the surge, or pre-mortem surge) [1] is an unexpected return of consciousness, mental clarity or memory shortly before death in individuals with severe psychiatric or neurological disorders.
The T cells had been modified to express genes that would allow the cells to proliferate in the body and destroy B cells including those causing the leukemia. Two patients went into remission, while the presence of leukemia in the third patient reduced by 70%. [95] [96] [non-primary source needed] [needs update]
Spontaneous remission, also called spontaneous healing or spontaneous regression, is an unexpected improvement or cure from a disease that usually progresses. These terms are commonly used for unexpected transient or final improvements in cancer .
The number of people with dementia is forecast to almost triple by 2050. Around 70% of these cases are likely to be Alzheimer’s disease, the most common form of dementia.
Complete remission does not mean the disease has been cured; rather, it signifies no disease can be detected with available diagnostic methods. [60] All subtypes except acute promyelocytic leukemia are usually given induction chemotherapy with cytarabine and an anthracycline such as daunorubicin or idarubicin . [ 60 ]
Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission (no symptoms or signs of disease). Sensitive molecular tests are either in development or available to test for MRD.